Stocktoria
AMGEN INC AMGN
AMGEN INC (AMGN) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the distress zone. It pays a dividend yielding 2.65% (safety: stretched). FY2025 revenue was $36.8B at a 21.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.27 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-10 | Guggenheim | Neutral (main) |
| 2026-08-07 | Citigroup | Neutral (main) |
| 2026-08-06 | Bernstein | Market Perform (main) |
| 2026-08-05 | UBS | Buy (main) |
| 2026-08-05 | TD Cowen | Buy (main) |
| 2026-08-05 | Truist Securities | Hold (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.039 |
| Retained earnings / assets | -0.277 |
| EBIT / assets | 0.1 |
| Equity / liabilities | 0.106 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| AMGN | AMGEN INC | 6/9 | 0.14 | 25.1 | +10% |
| GILD | GILEAD SCIENCES, INC. | 7/9 | 3.28 | 18.7 | +2.4% |
| BIIB | BIOGEN INC. | 4/9 | — | 24.7 | +2.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | 5/9 | 6.21 | 35.4 | +21.4% |
| EXEL | EXELIXIS, INC. | 6/9 | 7.69 | 17.6 | +7% |
| QGEN | QIAGEN N.V. | 7/9 | 5.06 | 19.1 | +5.7% |
| HALO | HALOZYME THERAPEUTICS, INC. | 5/9 | 3.02 | 28.1 | +37.6% |
About AMGEN INC
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
FAQ
Is AMGN financially healthy?
AMGEN INC's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does AMGN pay a dividend, and is it safe?
Yes. AMGEN INC pays a dividend yielding about 2.65% with a 66.5% payout ratio, rated “stretched” for safety.
How profitable is AMGN?
In FY2025, AMGEN INC had a net margin of 21.0% and a return on equity of 89.1%.
Is AMGN overvalued or undervalued?
AMGEN INC trades at about 29.2× trailing earnings — above its 10-year norm (10-year range 14.8×–69.2×, median 22.1×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for AMGN?
The average Wall-Street price target for AMGEN INC is $381.59, about 8.3% below the recent price, from 29 analysts (consensus: buy).
Is AMGN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on AMGEN INC: a Piotroski F-score of 6/9, an Altman Z″ in the distress zone, a P/E of about 25.1×, a dividend yield of 2.65%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.